Erythromycin Cyclocarbonate

• CAT Number: A000123
• CAS Number: 55224-05-0
• Molecular Formula: C38H65NO14
• Molecular Weight: 759.90
• Purity: ≥95%
• Target: Bacterial
• Storage: -20°C
• IUPAC Name: (1R,2R,5R,6S,7S,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-6-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-1,5,7,9,11,13-hexamethyl-3,15,17-trioxabicyclo[12.3.0]heptadecane-4,12,16-trione
• InChI: InChI=1S/C38H65NO14/c1-14-25-38(10)32(52-35(44)53-38)20(4)27(40)18(2)16-36(8,45)31(51-34-28(41)24(39(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-37(9,46-13)30(42)23(7)48-26/h18-26,28-32,34,41-42,45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30+,31-,32-,34+,36-,37-,38-/m1/s1
• InChIKey: NKLGIWNNVDPGCA-ZDYKNUMJSA-N
• SMILES: CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)C)OC(=O)O2)C

Erythromycin Cyclocarbonate（Cat No.:A000123）is a derivative of the macrolide antibiotic erythromycin, primarily used in pharmaceutical research. It is characterized by the presence of a carbonate group, which modifies the drug’s pharmacokinetics and potentially enhances its bioavailability. This compound maintains the core antimicrobial activity of erythromycin, making it effective against a broad spectrum of Gram-positive bacteria. Its unique structure also allows for deeper exploration of macrolide-related mechanisms and interactions. Erythromycin Cyclocarbonate is valuable for studies focused on antibiotic resistance, drug metabolism, and optimizing therapeutic strategies in bacterial infections.

Reference

1: Zhang W, Qiu L, Gong A, Yuan X. Isolation and characterization of a high-efficiency erythromycin A-degrading Ochrobactrum sp. strain. Mar Pollut Bull. 2017 Jan 30;114(2):896-902. doi: 10.1016/j.marpolbul.2016.10.076. PubMed PMID: 27863881.2: Pierattini EC, Francini A, Raffaelli A, Sebastiani L. Morpho-physiological response of Populus alba to erythromycin: A timeline of the health status of the plant. Sci Total Environ. 2016 Nov 1;569-570:540-7. doi: 10.1016/j.scitotenv.2016.06.152. PubMed PMID: 27366984.3: Chen D, Wu J, Liu W. [Biosynthesis-based production improvement and structure modification of erythromycin A]. Sheng Wu Gong Cheng Xue Bao. 2015 Jun;31(6):939-54. Review. Chinese. PubMed PMID: 26672369.4: Jiang M, Fang L, Pfeifer BA. Improved heterologous erythromycin A production through expression plasmid re-design. Biotechnol Prog. 2013 Jul-Aug;29(4):862-9. doi: 10.1002/btpr.1759. PubMed PMID: 23804312.5: Magee TV, Han S, McCurdy SP, Nguyen TT, Granskog K, Marr ES, Maguire BA, Huband MD, Chen JM, Subashi TA, Shanmugasundaram V. Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1727-31. doi: 10.1016/j.bmcl.2013.01.067. PubMed PMID: 23414806.6: Jiang M, Zhang H, Pfeifer BA. The logic, experimental steps, and potential of heterologous natural product biosynthesis featuring the complex antibiotic erythromycin A produced through E. coli. J Vis Exp. 2013 Jan 13;(71):e4346. doi: 10.3791/4346. PubMed PMID: 23354010; PubMed Central PMCID: PMC3582574.7: Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. Br J Clin Pharmacol. 2012 Dec;74(6):1053-62. doi: 10.1111/j.1365-2125.2012.04286.x. PubMed PMID: 22463376; PubMed Central PMCID: PMC3522819.8: Brüning J, Trepte TK, Bats JW, Schmidt MU. Erythromycin A dimethyl sulfoxide disolvate 1.43-hydrate. Acta Crystallogr Sect E Struct Rep Online. 2012 Mar 1;68(Pt 3):o700-1. doi: 10.1107/S1600536812005223. PubMed PMID: 22412590; PubMed Central PMCID: PMC3295479.9: Zhang H, Skalina K, Jiang M, Pfeifer BA. Improved E. coli erythromycin A production through the application of metabolic and bioprocess engineering. Biotechnol Prog. 2012 Jan-Feb;28(1):292-6. doi: 10.1002/btpr.702. PubMed PMID: 21905273.10: Wu J, Zhang Q, Deng W, Qian J, Zhang S, Liu W. Toward improvement of erythromycin A production in an industrial Saccharopolyspora erythraea strain via facilitation of genetic manipulation with an artificial attB site for specific recombination. Appl Environ Microbiol. 2011 Nov;77(21):7508-16. doi: 10.1128/AEM.06034-11. PubMed PMID: 21841022; PubMed Central PMCID: PMC3209160.11: Sugawara A, Sueki A, Hirose T, Nagai K, Gouda H, Hirono S, Shima H, Akagawa KS, Omura S, Sunazuka T. Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3373-6. doi: 10.1016/j.bmcl.2011.04.004. PubMed PMID: 21524580.12: Ma X, Ma S. Significant breakthroughs in search for anti-infectious agents derived from erythromycin A. Curr Med Chem. 2011;18(13):1993-2015. Review. PubMed PMID: 21517774.13: Zhang L, Jiao B, Yang X, Liu L, Ma S. Synthesis and antibacterial activity of new 4″-O-carbamates of 11,12-cyclic carbonate erythromycin A 6,9-imino ether. J Antibiot (Tokyo). 2011 Mar;64(3):243-7. doi: 10.1038/ja.2010.166. Erratum in: J Antibiot (Tokyo). 2012 Feb;65(2):115. PubMed PMID: 21245870.14: Zhang H, Wang Y, Wu J, Skalina K, Pfeifer BA. Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem Biol. 2010 Nov 24;17(11):1232-40. doi: 10.1016/j.chembiol.2010.09.013. PubMed PMID: 21095573.15: Luiz DB, Genena AK, Virmond E, José HJ, Moreira RF, Gebhardt W, Schröder HF. Identification of degradation products of erythromycin A arising from ozone and advanced oxidation process treatment. Water Environ Res. 2010 Sep-Oct;82(9):797-805. PubMed PMID: 20942335.16: Qi Y, Jiao B, Ma X, Cui W, Ma S. Synthesis and antibacterial activity of novel 4/’/’-O-carbamoyl erythromycin-A derivatives. Arch Pharm (Weinheim). 2010 Aug;343(8):458-64. doi: 10.1002/ardp.200900288. PubMed PMID: 20803622.17: Shiina I, Katoh T, Nagai S, Hashizume M. Evaluation of the efficiency of the macrolactonization using MNBA in the synthesis of erythromycin A aglycon. Chem Rec. 2009;9(6):305-20. doi: 10.1002/tcr.200900017. Erratum in: Chem Rec. 2010 Apr 26;10(2) doi: 10.1002/tcr.201090004. PubMed PMID: 20041452.18: Namikawa H, Sunazuka T, Kitamura Y, Suzuki T, Hamasaki Y, Yamazaki S, Omura S, Hatamochi A. Effect of erythromycin A and its new derivative EM201 on type I collagen production by cultured dermal fibroblasts. Arch Dermatol Res. 2010 Jul;302(5):341-8. doi: 10.1007/s00403-009-0977-z. PubMed PMID: 19578864.19: Zou X, Hang HF, Chu J, Zhuang YP, Zhang SL. Enhancement of erythromycin A production with feeding available nitrogen sources in erythromycin biosynthesis phase. Bioresour Technol. 2009 Jul;100(13):3358-65. doi: 10.1016/j.biortech.2009.01.064. PubMed PMID: 19268575.20: Pandey D, Haq W, Katti SB. New acylides: synthesis of 3-O-[gamma-(4-oxo-2-aryl-thiazolidin-3-yl)butyryl]erythromycin A derivatives. Beilstein J Org Chem. 2008;4:14. doi: 10.3762/bjoc.4.14. PubMed PMID: 18941486; PubMed Central PMCID: PMC2486485.